Physician profile
Sharnee E Straub
NPI 1962492207
$2,011.32
in general payments reported to CMS, 2019-2025
25 companies · $240 in 2025
The $240 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $224 · 2022: $369 · 2023: $671 · 2024: $508 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,418.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $488.20 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $193.60 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $159.69 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $139.56 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $138.22 | 2022-2023 | |
| Pfizer INC. | $129.51 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.86 | 2021-2025 | Ofev |
| Otsuka America Pharmaceutical, INC. | $84.49 | 2021-2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $67.64 | 2021-2023 | Farxiga |
| Abbott Laboratories | $60.84 | 2022-2024 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $57.67 | 2023 | Gemtesa |
| Axsome Therapeutics, INC. | $47.70 | 2024-2025 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $46.84 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.01 | 2023 | |
| Janssen Pharmaceuticals, INC | $34.36 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $34.12 | 2021-2023 | |
| Inspire Medical Systems, INC. | $30.67 | 2025 | Inspire |
| Astellas Pharma US INC | $29.45 | 2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $26.69 | 2021-2022 | |
| Corcept Therapeutics | $24.62 | 2024 | Korlym |
| Idorsia Pharmaceuticals US INC | $15.02 | 2023 | Quviviq |
| Amgen INC. | $14.65 | 2021 | |
| Exact Sciences Corporation | $14.57 | 2023 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $13.34 | 2024 | Voquezna |
| Amneal Pharmaceuticals LLC | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharnee Straub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.